|Bid||136.09 x 1100|
|Ask||136.23 x 900|
|Day's range||135.86 - 136.61|
|52-week range||119.59 - 158.34|
|Beta (5Y monthly)||0.91|
|PE ratio (TTM)||20.34|
|Earnings date||31 Jan 2024 - 05 Feb 2024|
|Forward dividend & yield||2.84 (2.09%)|
|Ex-dividend date||16 Jan 2024|
|1y target est||142.64|
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Scipher Medicine, a precision immunology company, today announced a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis (RA).
Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.
Universal DX ("UDX"), a biotech company on a mission to transform cancer into a curable disease, today announced a strategic collaboration with Quest Diagnostics ("Quest") (NYSE: DGX), the nation's leading provider of diagnostic information services, designed to improve colorectal cancer screening in the United States – for which more than 110 million people may be eligible.i